An interventional study of Creatine Monohydrate and Maltodextrin (Placebo) in Acute Kidney Injury and Exertional Heat Illness, sponsored by University of Northern Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by University of Northern Iowa · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 187th largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 106 with no phase, reaches primary completion later than 35 of the 87 other live ones, and was the 358th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
University of Northern Iowa is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
University of Northern Iowa has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if one week of creatine monohydrate supplementation alters inflammation, markers of acute kidney injury (AKI) risk, and cognitive performance in active, young, healthy volunteers. The main questions it aims to answer are:
Researchers will compare creatine monohydrate to a placebo (maltodextrin) to see if it alters inflammation, risk of acute kidney injury, and cognition after exercise in the heat.
Participants will :
The outlined research questions/ hypotheses will require 3 visits (1 baseline, then 2 experimental trials) to the UNI Exercise Physiology Lab.
The first (baseline) visit will involve completing paperwork (informed consent, health history questionnaire, physical activity readiness questionnaire; PAR-Q+), familiarization of cognitive assessment techniques, anthropometric assessments, and a maximal effort, graded exercise test.
Baseline Visit:
- Height and weight will be measured using a standing stadiometer and InBody bioimpedance analyses full body analyzer
Exercise Visits (Creatine and Placebo, Visits 2 \& 3):
Each experimental exercise visit consists of supplementation with a standardized breakfast and 90-minutes of exercise on a stationary cycle ergometer located in the heat chamber of the Exercise Physiology Lab. To ensure participant safety and consistency in data collection, the following outlines the environmental conditions, safety considerations, exercise protocols, and measurement procedures that will be followed for each exercise visit.
Environmental Conditions:
All exercise testing will occur in a controlled environmental chamber set to simulate a hot exercise environment. Conditions within the chamber will be maintained at 38 °C (100.4 °F) and 40% relative humidity (WBGT: \~30.2 °C) and monitored continuously via Kestrel Drop temperature and humidity monitoring device.
Supplement Administration:
Exercise Visits (visits 2 and 3):
Urine Specific Gravity (USG) will be measured using a refractometer following standard procedures to confirm hydration.
4. Bioelectrical Impedance Analysis: Participants will step on an InBody device which will measure % body fat.
5. Sleep questionnaire: Participants will be asked to fill out a sleep questionnaire to get an idea if creatine altered sleep quality or duration.
6. Standardized breakfast, water, and supplement Administration (1 hour prior to exercise)
a. Once adequate hydration is confirmed, participants will consume the assignment supplement (5 grams of creatine or placebo) with a standardized breakfast. After full consumption of food and supplement, the research team will start the 1-hour timer to ensure that a full 60-minutes is waited before starting exercise.
7. After Supplementation but Prior to Exercise:
i. Participants will sit for 10-minutes. ii. Blood pressure will be recorded and measured. iii. A capillary blood sample will be taken from the earlobe or fingertip to measure blood composition.
c. Urine Collection: In a private restroom, participants will void their bladder into a beaker. Urine will then be stored at -80 °C until later analyses for markers of acute kidney injury.
d. Nude Body Weight: Participants will be instructed to enter a private bathroom to measure nude body weight and self- insert a rectal thermistor to measure core temperature: e. Monitoring Devices: i. Participants will be fitted with a Polar chest-strap that contains a heart rate monitor.
ii. Participants will be fitted with 4, non-invasive skin temperature iButton sensors, placed on the chest, arm, thigh, and leg.
8.Pre-Exercise Baseline Measures
i. Profile of Mood States (POMS) Questionnaire ii. Color-Word Stroop Test (CWST) (a cognition test) iii. Thermal Comfort \& Strain Scale (TCS) (to understand perceived heat stress) iv. Rating of Perceived Exertion (RPE) v. Heart Rate (HR) and Core Temperature (Tc) vi. Room Temperature and Humidity vii. Visual Analogue Scale for Fatigue (VAS-F) viii. Gastrointestinal Symptoms Questionnaire (GIQ) ix. Environmental Symptoms Questionnaire (ESQ)
9. Exercise Protocol
i. HR ii. Tc iii. RPE iv. TCS v. Room Temperature and Humidity vi. Visual Analogue Scale for Fatigue (VAS-F) d. At the end of each 30-minute cycle, participants will complete the CWST while cycling.
e. During minutes 15-25 of each 30-minute cycle (the last 5-min at 4 W/kg and the first 5-min at 8 W/kg), the participant will be hooked up to the same mouthpiece and nose clip used for baseline aerobic testing. This will be used to calculate estimated metabolic rate during the trial.
10. Post-Exercise Heat Measures (in heat chamber):
i. HR ii. Tc iii. RPE iv. TCS v. CWST vi. Room Temperature and Humidity vii. Visual Analogue Scale for Fatigue (VAS-F) viii. POMS ix. GIQ x. ESQ xi. Blood Pressure xii. I-STAT capillary blood measurement
11.Post-Exercise Hydration Assessments
During this time, participants will be allowed to change clothing
12. After providing urine and changing, participants will complete all cognition assessments.
13. 1-Hour Post-Exercise Hydration Assessments
a. Another blood collection measurement will be conducted. b. Participants will provide a urine sample to reassess hydration using USG, urine flow rate, and store urine for future analyses.
14. Subjects will then be scheduled for their second exercise visit (following 28-day washout period- 21 day washout then 7 days of supplementation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will ingest 20 grams per day of creatine monohydrate for 7 days, then 1 day of 5 grams before the exertional heat trial.
Dietary Supplement: Creatine Monohydrate
Participants will ingest 20 grams per day of maltodextrin for 7 days, then 1 day of 5 grams before the exertional heat trial.
Dietary Supplement: Maltodextrin (Placebo)
20 grams per day of creatine monohydrate for 7 days, followed by 1 day of 5 grams of supplementation.
Participants will ingest 20 grams per day for 7 days, followed by 1 day of 5 grams.
Change in Urine Biomarker of Acute Kidney Injury Risk from Creatine Use Prior to Exercise in the Heat (The mathematical product of IGBFP7 and TIMP-2 [IGFBP7 x TIMP-2; NephroCheck®])
Concentrations of both IGBFP7 and TIMP-2 will be measured in the urine. The mathematical product of these values (IGFBP7 x TIMP-2) will then be calculated and reported for each time point.
Time frame: Change in urinary IGBP7 x TIMP-2 from immediately before exercise in the heat to 1 hour after exercise in the heat.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Creatine monohydrate
University of Northern Iowa